Tysabri and PML: Understanding the Statute of Limitations in Virginia

Latest update (2026-07)

From General Health Awareness to Specific Legal Concerns

For decades, general health and science information has served as the foundation for public understanding of medical risks and legal recourse. This broad educational framework has enabled individuals to recognize when a therapeutic intervention may carry unintended consequences, particularly in the context of mass-produced pharmaceuticals. The transition from this generalized awareness to a more focused occupational concern arises when a specific medication becomes associated with a serious adverse event, prompting affected parties to seek clarity on their legal options. In the case of Tysabri, a biologic therapy used in certain chronic conditions, exposure has been linked to an elevated risk of progressive multifocal leukoencephalopathy (PML), a rare but severe brain infection. For individuals in Virginia who have used this medication, the question of legal action hinges on the statute of limitations—the time window within which a claim must be filed. This temporal constraint is critical for those who may have developed PML after Tysabri exposure, as delays in diagnosis or recognition of the link can complicate legal proceedings. Thus, the legacy of general health education now pivots to a specific occupational exposure concern: understanding how the statute of limitations applies to Tysabri-related PML settlements in Virginia. This shift requires careful consideration of when the injury was discovered or should have been discovered, marking a transition from broad informational context to targeted legal and medical risk assessment.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is essential. PML is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis typically involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. Because PML can progress rapidly, the label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and understanding of risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways and Adequacy of Warnings

The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and uncontrolled replication in the brain. This immunosuppressive effect, combined with the patient's own immune status, creates the conditions for PML development. The label notes that PML typically occurs only in immunocompromised patients, and Tysabri's mechanism contributes to this state (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning on Tysabri's label explicitly states that the drug increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also identifies the three key risk factors and mandates monitoring and immediate withholding of the drug if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program further ensures that patients receive a Medication Guide and acknowledge the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether these warnings were sufficiently communicated to individual patients or whether the risks were adequately balanced against expected benefits, particularly in cases where PML developed despite adherence to monitoring protocols.

Settlement Considerations and Statute of Limitations in Virginia

For patients in Virginia who have developed PML after Tysabri treatment, settlement considerations involve the timeline between exposure and documented harm. PML can occur months to years after starting Tysabri, with risk increasing after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The statute of limitations for personal injury claims in Virginia is generally two years from the date the injury was discovered or reasonably should have been discovered. This means that affected patients must file any legal action within two years of learning that their PML was linked to Tysabri. Given the latency of PML symptoms and the time needed for diagnosis, patients should promptly seek legal counsel to preserve their rights. Settlements in Tysabri-related PML cases often consider the severity of disability, medical expenses, lost income, and the adequacy of warnings provided to the patient. The boxed warning and TOUCH program documentation may be relevant in assessing whether the manufacturer fulfilled its duty to warn. Patients should gather all medical records, including dates of Tysabri infusions, MRI results, and JC virus antibody testing, to establish the timeline of exposure and harm.

Conclusion and Next Steps

Tysabri carries a known risk of PML, with specific risk factors and monitoring requirements outlined in its labeling. For Virginia patients who have suffered PML, the statute of limitations imposes a two-year window from discovery of the injury. Understanding the medical evidence and risk factors is crucial for evaluating potential settlement options. Patients should consult with both medical and legal professionals to assess their individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For Tysabri-related PML, this means you must file a claim within two years of learning that your PML was linked to Tysabri.

What are the risk factors for developing PML while on Tysabri?

The three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the Tysabri prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

Related Articles

References

  1. Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Provide your details below to see if you qualify.

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.